BG108234A - 3,7-диазабицикло[ 3.3.1] състави включващи антиаритмични съединения - Google Patents

3,7-диазабицикло[ 3.3.1] състави включващи антиаритмични съединения Download PDF

Info

Publication number
BG108234A
BG108234A BG108234A BG10823403A BG108234A BG 108234 A BG108234 A BG 108234A BG 108234 A BG108234 A BG 108234A BG 10823403 A BG10823403 A BG 10823403A BG 108234 A BG108234 A BG 108234A
Authority
BG
Bulgaria
Prior art keywords
composition
acid
diazabicyclo
carrier
oxa
Prior art date
Application number
BG108234A
Other languages
Bulgarian (bg)
English (en)
Inventor
Christina Hovdal
Anna Lundgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BG108234A publication Critical patent/BG108234A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG108234A 2001-04-12 2003-10-06 3,7-диазабицикло[ 3.3.1] състави включващи антиаритмични съединения BG108234A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BG108234A true BG108234A (bg) 2005-04-30

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108234A BG108234A (bg) 2001-04-12 2003-10-06 3,7-диазабицикло[ 3.3.1] състави включващи антиаритмични съединения

Country Status (26)

Country Link
US (1) US20050037067A1 (xx)
EP (1) EP1389212B1 (xx)
JP (1) JP2005500262A (xx)
KR (1) KR20030088498A (xx)
CN (1) CN1514839A (xx)
AR (1) AR035806A1 (xx)
AT (1) ATE332902T1 (xx)
BG (1) BG108234A (xx)
BR (1) BR0208828A (xx)
CA (1) CA2443473A1 (xx)
CZ (1) CZ20032774A3 (xx)
DE (1) DE60213084T2 (xx)
EE (1) EE200300495A (xx)
HU (1) HUP0303486A3 (xx)
IL (1) IL158033A0 (xx)
IS (1) IS6989A (xx)
MX (1) MXPA03009209A (xx)
NO (1) NO20034529L (xx)
NZ (1) NZ528561A (xx)
PL (1) PL366629A1 (xx)
RU (1) RU2003129230A (xx)
SE (1) SE0101329D0 (xx)
SK (1) SK12562003A3 (xx)
TW (1) TWI257391B (xx)
WO (1) WO2002083689A1 (xx)
ZA (1) ZA200307756B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2014157603A1 (ja) * 2013-03-29 2014-10-02 アステラス製薬株式会社 経口投与用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
HUP0202214A3 (en) * 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
KR20030088498A (ko) 2003-11-19
BR0208828A (pt) 2004-03-09
EP1389212B1 (en) 2006-07-12
IS6989A (is) 2003-10-10
HUP0303486A3 (en) 2005-04-28
SK12562003A3 (sk) 2004-03-02
NO20034529D0 (no) 2003-10-09
US20050037067A1 (en) 2005-02-17
IL158033A0 (en) 2004-03-28
CN1514839A (zh) 2004-07-21
JP2005500262A (ja) 2005-01-06
ZA200307756B (en) 2005-01-03
RU2003129230A (ru) 2005-04-10
PL366629A1 (en) 2005-02-07
DE60213084D1 (de) 2006-08-24
AR035806A1 (es) 2004-07-14
MXPA03009209A (es) 2004-01-29
ATE332902T1 (de) 2006-08-15
NO20034529L (no) 2003-12-08
DE60213084T2 (de) 2007-01-11
WO2002083689A1 (en) 2002-10-24
NZ528561A (en) 2005-03-24
HUP0303486A2 (hu) 2004-01-28
EE200300495A (et) 2003-12-15
SE0101329D0 (sv) 2001-04-12
TWI257391B (en) 2006-07-01
CZ20032774A3 (cs) 2004-01-14
EP1389212A1 (en) 2004-02-18
CA2443473A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
RU2506264C2 (ru) Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)
EP1819323B2 (en) Pharmaceutical composition containing an anti-nucleating agent
TWI237025B (en) New crystalline forms of antiarrhythmic compounds
BG108234A (bg) 3,7-диазабицикло[ 3.3.1] състави включващи антиаритмични съединения
US20040039199A1 (en) Oxabispidine compound useful in the treatment of cardiac arrhythmias
TW201722965A (zh) 用於抗菌應用之化合物
KR20040005917A (ko) 항부정맥 화합물로서의 3,7-디아자비시클로 [3,3,1]제제
ZA200002749B (en) A dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound.
US9125916B2 (en) Methods of treating hypertrophic cardiomyopathy
AU2002253750A1 (en) 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
WO2024068553A1 (en) Solubilizing compounds
WO2016141889A1 (zh) 一种新型三唑并嘧啶衍生物及其应用
CN116710425A (zh) 用于治疗涉及兰诺定受体的病症的药剂
ZA200307757B (en) 3,7-Diazabicyclo[3.3.1]formulations as antiarrhythmic compounds.
AU2002253749A1 (en) 3,7-diazybicyclo [3.3.1] formulations as antiarrhytmic compounds